32 assets in Myeloid Leukemia

Therapeutic assets addressing Myeloid Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Fludarabine Myeloid Leukemia	M.D. Anderson Cancer Center	P2/3	BBB (72)
Cyclophosphamide Myeloid Leukemia	Actinium Pharmaceuticals	P2/3	BB (70)
Cytarabine Myeloid Leukemia	M.D. Anderson Cancer Center	P3	BB (68)
Nivestim Myeloid Leukemia	M.D. Anderson Cancer Center	P2	BB (68)
Sirolimus Myeloid Leukemia	Masonic Cancer Center, University of Minnesota	P2	BB (65)
Melphalan Myeloid Leukemia	Dana-Farber Cancer Institute	P2	B (63)
Enasidenib Myeloid Leukemia	Tian Yi Zhang	P3	B (62)
Azacitidine Myeloid Leukemia	Jacqueline Garcia, MD	P3	B (61)
Busulfanum Myeloid Leukemia	Dana-Farber Cancer Institute	P2	B (60)
Apamistamab Myeloid Leukemia	Actinium Pharmaceuticals	P2/3	B (57)
Allopurinol Myeloid Leukemia	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Blinatumomab Myeloid Leukemia	M.D. Anderson Cancer Center	P1/2	CCC (52)
Gilteritinib Myeloid Leukemia	M.D. Anderson Cancer Center	P1/2	CCC (50)
Idarubicin Myeloid Leukemia	M.D. Anderson Cancer Center	P1/2	CCC (50)
Venetoclax Myeloid Leukemia	M.D. Anderson Cancer Center	P1/2	CCC (50)
Asciminib Myeloid Leukemia	M.D. Anderson Cancer Center	P1/2	CC (47)
Mitoxantrone Myeloid Leukemia	University of Colorado, Denver	P1	CC (46)
Daratumumab Myeloid Leukemia	Masonic Cancer Center, University of Minnesota	P1	CC (44)
Lispro-Ph20 Component Rhuph20 Myeloid Leukemia	Masonic Cancer Center, University of Minnesota	P1	CC (44)
Mesna Myeloid Leukemia	Dana-Farber Cancer Institute	P1	CC (43)
Thiotepa Myeloid Leukemia	Dana-Farber Cancer Institute	P1	CC (43)
Treg-Enriched Donor Cell Myeloid Leukemia	Dana-Farber Cancer Institute	P1	CC (43)
bh-30236 Myeloid Leukemia	BlossomHill Therapeutics	P1	CC (41)
Cytokine Induced Memory-Like Natural Killer Cells Myeloid Leukemia	Dana-Farber Cancer Institute	P1	CC (41)
Cytokine-Induced Memory-Like Natural Killer Cells Myeloid Leukemia	Dana-Farber Cancer Institute	P1	CC (41)
Eganelisib Myeloid Leukemia	Jacqueline Garcia, MD	P1	CC (41)
Olverembatinib Myeloid Leukemia	Ascentage Pharma Group Inc.	P1	CC (41)
Ziftomenib Myeloid Leukemia	Kura Oncology, Inc.	P1	CC (41)
cc-90011 Myeloid Leukemia	Celgene	P1	CC (40)
Momelotinib Myeloid Leukemia	M.D. Anderson Cancer Center	P1/2	C (39)
Donor T Cells Myeloid Leukemia	Dana-Farber Cancer Institute	P1	D (30)
ft538 Myeloid Leukemia	Masonic Cancer Center, University of Minnesota	P1	D (29)